Gene therapy injection aims to restore pigment in Children's eyes

NCT ID NCT07313618

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a single injection of JWK010 gene therapy in 18 children aged 5 to 12 with oculocutaneous albinism type 1 (OCA1). OCA1 is caused by a gene change that prevents the body from making pigment, leading to vision problems and light sensitivity. The therapy is designed to help eye cells produce the missing pigment, potentially improving vision and eye structure. The main goal is to check safety, with secondary goals looking at vision changes and pigment restoration.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULOCUTANEOUS ALBINISM (OCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

oculocutaneous albinism oculocutaneous albinism type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULOCUTANEOUS ALBINISM (OCA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

Contact Phone: •••-•••-•••• Email: •••••@•••••